UP!

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2019 2019-10-22 Future report Set alerts
Q2 2019 2019-07-25 0.34 0.00
Q1 2019 2019-04-25 0.09 -0.89
Q4 2018 2019-02-13 0.43 -0.35
Q3 2018 2018-10-24 0.40 -0.17
Q2 2018 2018-07-25 0.35 -0.08
Q1 2018 2018-04-25 0.24 -0.10
Q4 2017 2018-02-07 0.42 -0.22
Q3 2017 2017-10-25 0.40 -0.26
Q2 2017 2017-07-26 0.34 -0.15

Ratings

2016-04-21 Reiterated Rating Roth Capital Buy
2016-04-05 Downgrade Raymond James Outperform to Market Perform
2016-04-05 Lower Price Target Roth Capital Buy $44.00 to $39.00
2016-04-05 Downgrade Raymond James Financial Inc. Outperform to Market Perform
2016-03-01 Reiterated Rating Roth Capital Buy
2016-01-20 Reiterated Rating Roth Capital Buy
2016-01-12 Lower Price Target Roth Capital Buy $53.00 to $50.00
2015-12-16 Reiterated Rating Roth Capital Buy
2015-10-22 Reiterated Rating Roth Capital Buy $51.00 to $53.00
2015-10-15 Reiterated Rating Roth Capital Buy $51.00 to $53.00
2015-09-10 Reiterated Rating Roth Capital Buy
2015-07-23 Boost Price Target Roth Capital Buy $45.00 to $51.00
2015-07-15 Reiterated Rating Roth Capital Buy
2015-04-22 Set Price Target Roth Capital Buy $42.00 to $45.00
2015-03-27 Set Price Target Roth Capital Buy $42.00
2015-01-26 Set Price Target Roth Capital Buy $42.00
2015-01-06 Set Price Target Roth Capital Buy $36.00 to $42.00
2014-10-22 Reiterated ROTH Capital Buy $33 to $36
2014-10-22 Boost Price Target Roth Capital Buy $33.00 to $36.00
2013-11-26 Boost Price Target Raymond James $21.00 to $25.00
2013-10-25 Boost Price Target Roth Capital Buy $15.00 to $22.00
2011-09-01 Initiated Stifel Nicolaus Hold
2009-07-13 Initiated Cowen & Co Neutral
2009-06-03 Reiterated Roth Capital Buy $10.50 to $12.50
2009-05-01 Upgrade William Blair Mkt Perform to Outperform
2009-05-01 Upgrade Needham Hold to Buy
2009-04-06 Reiterated Roth Capital Buy $12.50 to $10.50
2009-01-21 Reiterated Roth Capital Buy $21 to $12.50
2009-01-20 Reiterated Avondale Mkt Perform $17 to $10.50
2009-01-09 Reiterated UBS Buy $20 to $16
2009-01-09 Reiterated Stanford Research Buy $20 to $16
2008-12-19 Initiated William Blair Mkt Perform
2008-09-24 Downgrade Needham Buy to Hold
2008-09-04 Reiterated Roth Capital Buy $26 to $28
2008-09-03 Reiterated Roth Capital Buy $26 to $28
2008-08-01 Reiterated Roth Capital Buy $25 to $26
2008-07-14 Downgrade Avondale Mkt Outperform to Mkt Perform $24
2008-05-02 Reiterated Roth Capital Buy $22 to $25
2008-05-01 Reiterated Avondale Mkt Outperform $22 to $24
2008-02-12 Upgrade Avondale Partners Mkt Perform to Mkt Outperform $20 to $22
2008-02-01 Initiated Avondale Partners Mkt Perform $20
2016-04-21 Reiterated Rating Roth Capital Buy
2016-04-05 Downgrade Raymond James Outperform to Market Perform
2016-04-05 Lower Price Target Roth Capital Buy $44.00 to $39.00
2016-04-05 Downgrade Raymond James Financial Inc. Outperform to Market Perform
2016-03-01 Reiterated Rating Roth Capital Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
HAWKINS JAMES B Chief Executive Officer 1.98%  (639257) BABY / DRAD / IRIX / IRMD / OSIS /
CHUNG DONG CHUNE CHRISTOPHER Vice President Medical Affairs 0.42%  (136373) BABY /
MURPHY STEVEN J Vice President Finance and CFO 0.35%  (113292) BABY /
TRAVERSO KENNETH M VP Marketing and Sales 0.34%  (109855) BABY /
Kennedy Jonathan Sr. VP, CFO 0.33%  (107588) BABY / IRMD / ISIL /
Buhler John T President and COO 0.31%  (100610) BABY /
LUDLUM KEN 0.28%  (89825) BABY / CDNA /
MOORE WILLIAM M 0.28%  (89402) BABY / CMD / IRIX / ULGX /
Noll Austin Francis III VP/GM Neurology 0.25%  (81901) BABY /
MINCE WILLIAM L Vice President Operations 0.21%  (67162) BABY /
GUNST ROBERT A 0.17%  (55850) BABY /
MICHAEL MARK D 0.14%  (45000) BABY /
Engibous Doris 0.07%  (21750) BABY /
McDonnell Leslie L VP/GM Newborn Care 0.05%  (16836) BABY /
PAUL BARBARA R 0.02%  (7460) BABY / QHC /

Comments